Special Issue

Drug Permeability and Metabolism in the Gut

Message from the Guest Editor

Intestinal permeability is a crucial factor for orally administered drugs, and can in some cases be assisted by uptake transporters or limited by efflux transporters and metabolic enzymes in the gut. It is crucial to identify gut enzymes that induce the biotransformation of orally administered drug molecules as well as intestinal transporters and their pharmacokinetic, pathophysiological, and pharmacogenetic roles in drug transport. Besides scenarios where regional-dependent intestinal permeability occurs, lately, regional differences in human intestinal drug metabolism have been identified as well. While drug metabolism in the liver has been widely researched, the pharmaceutical research has further to go in terms of adopting a standardised approach for the characterisation and quantitative prediction of intestinal metabolism. In this Special Issue, work which focuses on intestinal drug permeability as well as intestinal metabolism is of great interest. Authors are welcome to contribute both original research and review articles.

Guest Editor

Dr. Milica Markovic

Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

Deadline for manuscript submissions

closed (15 March 2023)

Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed

mdpi.com/si/133751

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/metabolites



Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed

mdpi.com/journal/metabolites

MDPI

About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo
Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).